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Abstract
We conducted a retrospective study on the prevalence and
correlates of transmitted drug resistance among newly-diag-
nosed antiretroviral naive human immunodeﬁciency virus (HIV)
patients in Northern Greece, during the period 2009–11.
Transmitted drug resistance was documented in 21.8% of
patients enrolled, affecting approximately 40% of subtype A
HIV-1-infected individuals. Overcoming challenges due to the
ongoing ﬁnancial crisis, effective preventive measures should be
implemented to control further dissemination of resistant HIV
strains.
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Introduction
Europe-wide surveillance data estimated the prevalence of
transmission of drug-resistant human immunodeﬁciency virus
type 1 (HIV-1) in Europe to be stabilizing at levels as high as
8.4% (95% CI 7.4–9.5%) for the period 2002–06 [1]. Studies
reporting on more recent nationwide data provided compa-
rable estimates for transmitted drug resistance (TDR) across
Europe ranging from 5.6% to 12.4% [2–6].
Previously published surveillance data from Northern
Greece estimated the prevalence of TDR in newly diagnosed
antiretroviral naive patients to be 12.5% during the period
2000–07; time trends suggested an increase in rates of TDR
[7].
The purpose of the present retrospective study was to
report on the evolution of TDR prevalence during the period
2009–11 and to assess correlates of TDR in Northern Greece.
Patients and Methods
Two hundred and thirty-eight unselected individuals who were
diagnosed for the ﬁrst time with HIV-1 infection between 2009
and 2011 were eligible for this study. Clinical and epidemio-
logical data were collected in collaboration with the AHEPA
University Hospital HIV clinic [8].
Samples obtained within 6 months since diagnosis under-
went population sequencing of HIV-1 protease and partial
reverse transcriptase (RT) region (TRUGENEe HIV-1 geno-
typing kit; Siemens and Viroseqe HIV Genotyping kit; Abbott
Molecular), according to the manufacturer’s instructions. The
CALIBRATED POPULATION RESISTANCE TOOL Version 6.0 (http://
hivdb.stanford.edu) was used to analyse sequences for the
presence of TDR mutations according to the 2009 update of
the Surveillance Drug Resistance Mutation list [9]. As previ-
ously described [7], the Stanford University HIV drug resis-
tance database subtyping tool and the REGA HIV-1 subtyping
tool version 2.0 were used for classiﬁcation of HIV strains into
subtype B, subtype A and non-A/non-B subtype.
Binomial exact 95% conﬁdence intervals were calculated for
proportions. Time trends were evaluated with the Cochran–
Armitage trend test. Parameters including calendar year of
diagnosis, age at diagnosis, gender, risk factor for acquisition of
HIV infection, country of origin, HIV-1 subtype, baseline CD4
count and viral load were evaluated as predictors of TDR in
univariate and multivariate logistic regression models.
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All analyses were conducted in IBM/SPSS STATISTICS Version 19.
Results
Study population characteristics are presented in Table 1.
The prevalence of TDR to any drug class was 21.8% (52/238,
95% CI 16.8–27.6%). TDR mutations conferring resistance to
nucleoside RT inhibitors (NRTIs) were identiﬁed in 14.3% (34/
238, 95% CI 10.1–19.4%), to non-nucleoside RT inhibitors
(NNRTIs) in 18.9% (45/238, 95%CI 14.1–24.5%) and to protease
inhibitors in 1.2% (3/238, 95% CI 0.3–3.6%). HIV strains
harbouring dual class (NRTI and NNRTI) TDR mutations were
present in 11.8% (28/238, 95% CI 8–16.6%), whereas only one
patient with triple class TDR mutations was identiﬁed. No
signiﬁcant time trends were observed during the study period in
the prevalence of TDR overall and per drug class.
The most frequently encountered TDR mutations included
T215 revertants (31/238: 23 T215C, 4 T215S, 2 T215D and 2
T215E), Y181C (27/238) and K103N (15/238). Notably, T215
revertant mutations coexisted with Y181C in 25 cases.
Predictors of TDR tested in univariate logistic regression
models are presented in Table 2. Subtype A infection was
strongly associated with the presence of TDR mutations (OR
7.10, 95% CI 3.31–15.25, p <0.001) and remained nominally
signiﬁcant in multivariable analyses adjusted for gender, risk
factor for HIV infection, country of origin, age at diagnosis,
baseline viral load and baseline CD4 count. The prevalence of
TDR among subtype A HIV-1 strains was 40.8% compared
with 8.8% for subtype B strains and 7.4% for non-A/non-B.
Discussion
In the present study we found a substantial increase in
the levels of TDR among newly diagnosed antiretroviral naive
HIV-1-infected individuals in our region from 2009 to 2011
compared with the period 2000–07 (21.8% vs 12.5%) [7]. This
increase was driven by an increase in NNRTI (18.9% vs 5.4%)
and NRTI resistance (14.3% vs 7.6%); a reduction was
observed in protease inhibitor resistance (1.2% vs 3.3%).
The rates of TDR observed in our region exceed those
reported in a multicentre study conducted in Athens from
2000 to 2010 (21.8% vs 6.4%, 13th European AIDS Confer-
ence, abstract PE5.1/3), as well as results reported by several
recent studies across Europe [2–6]. Interestingly, data from a
TDR surveillance study in Ontario covering the period 2002–
09 demonstrated a sharp increase in TDR prevalence during
the last two study years (27.3% vs 9.5%) [10]. This increase
was driven by an increase in NRTI and NNRTI resistance and
parallels our study results with mutations such as T215
revertants and K103N being among the most prevalent. On
the other hand, the prevalence of drug resistance to two drug
classes was low compared with our study (2.7% vs 11.8%).
TABLE 1. Patient characteristics
Overall 2009 2010 2011
Patients enrolled 238 49 105 84
Mean age at diagnosis, years (SD) 36.7 (12) 37.3 (12.1) 35.4 (11.5) 37.9 (12.6)
Gender
Male 220 (92.4%) 42 (85.7%) 98 (93.3%) 80 (95.2%)
Female 18 (7.6%) 7 (14.3%) 7 (6.7%) 4 (4.8%)
Risk factors
Men who have sex with men 143 (60.1%) 34 (69.4%) 70 (66.7%) 39 (46.4%)
Heterosexual 33 (13.9%) 5 (10.2%) 12 (11.4%) 16 (19%)
Injecting drug user 14 (5.9%) 4 (8.2%) 2 (1.9%) 8 (9.5%)
Other/Unknown 48 (20.2%) 6 (12.2%) 21 (20%) 21 (25%)
Country of origin
Greece 216 (90.8%) 43 (87.8%) 95 (90.5%) 78 (92.9%)
Other 22 (9.2%) 6 (12.2%) 10 (9.5%) 6 (7.1%)
Subtype
B 113 (47.5%) 25 (51%) 47 (44.8%) 41 (48.8%)
A 98 (41.2%) 20 (40.8%) 43 (41%) 35 (41.7%)
Other 27 (11.3%) 4 (8.2%) 15 (14.3%) 8 (9.5%)
Median baseline CD4 count IQR 427 (246–613) 395 (191–626) 438 (272–647) 400 (257–533)
Mean baseline HIV RNA log10, SD 4.84 (0.88) 4.82 (0.94) 4.84 (0.85) 4.87 (0.90)
TABLE 2. Predictors of transmitted drug resistance to any
drug class
Predictor
Univariate analysis
Odds ratio (95% CI) p value
Subtype (reference subtype B)
Subtype A 7.10 (3.31–15.25) <0.001
Other 0.82 (0.17–4.00) 0.810
Risk factor (reference men who have sex with men)
Heterosexual contact 2.25 (0.99–5.09) 0.053
Injecting drug user 2.18 (0.68–7.01) 0.189
Other/Unknown 0.56 (0.22–1.45) 0.233
Age at diagnosis 0.99 (0.97–1.02) 0.608
Gender (reference male) 1.89 (0.67–5.31) 0.226
Baseline CD4 1.00 (0.99–1.01) 0.986
Log10 HIV RNA 0.95 (0.66–1.35) 0.754
Country of origin (reference Greece)
Other 1.77 (0.68–4.61) 0.240
Calendar year (reference 2011)
2009 0.87 (0.38–2.00) 0.740
2010 0.71 (0.35–1.41) 0.325
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E169–E172
E170 Clinical Microbiology and Infection, Volume 19 Number 3, March 2013 CMI
Data from the UK covering the same period indicate that the
prevalence of TDR tends to stabilize over the most recent
study years and T215 revertants were the most prevalent TDR
mutations despite the marked decrease in stavudine and
zidovudine use [2].
Although HIV-1 subtype A and subtype B contributed
almost equally to new HIV diagnoses, subtype A infection was
associated with TDR in approximately one-half of the cases,
whereas only 8.8% of subtype B strains harboured drug
resistance mutations. No further risk factors for transmission
of drug resistance mutations were identiﬁed. The high TDR
rates reported in our study could be attributed to the spread
of resistant strains within transmission networks, as suggested
by the TDR mutation patterns persistent within our study
population [7].
The increase in TDR prevalence in our region coincides
with a profound ﬁnancial crisis in Greece, which is character-
ized by a drastic reduction in the gross domestic product, a
sharp rise in unemployment—particularly in the young, drastic
cuts in health expenses and a substantial impact on the health
of the population [11]. An HIV outbreak affecting individuals at
the social margin such as intravenous drug users and
immigrants was recently documented in Athens [12]. In
contrast, the TDR rates observed in our study are strongly
associated with subtype A, which circulates in the native Greek
population and along with subtype B dominate the Greek HIV
epidemic [7,13]. Factors linked with reduced adherence to
therapy and retention to HIV care, as well as high-risk sexual
behaviours may be responsible for the wide spread of TDR in
our population [11].
Some limitations of our work include the study design,
which was based on a retrospective convenience sample, the
use of the date of resistance testing rather than the time of
seroconversion and the use of population sequencing, which
may underestimate the presence of drug resistance mutations.
Furthermore, we were not able to evaluate the impact of acute
versus chronic HIV infection as a predictor of TDR; evidence
suggests that acutely infected patients may be a group with
signiﬁcant implications for TDR spread [14].
Taking into consideration these limitations, the increased
rates of TDR underline the importance of surveillance on a
regional level and in the context of the ongoing ﬁnancial crisis
raise concerns about further dispersion of resistant strains and
may have implications for the success of antiretroviral therapy
[15]. Our preliminary data point out the need to enhance the
existent HIV control programme to allay the repercussions of
the crisis and to support public health planners and commu-
nity-driven initiatives to design and implement effective
prevention strategies directed to identify undiagnosed cases
and to increase the awareness of individuals under care.
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